**6. Conclusion**

The aforementioned clinical recommendations are based on relevant data, scientific evidence, available literature and the empirical experience of the authors. Despite the effort, neither standard nor recommended procedure may still be defined.

[3] Otto S et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence—A multi-centre study. Journal of Cranio-Maxillo-Facial

Osteonecrosis of the Jaws

81

http://dx.doi.org/10.5772/intechopen.75878

[4] Ruggiero LS et al. American association of oral and maxillofacial surgeons positions paper on bisphosphonate-related osteonecrosis of the jaws—2009 Update. Journal of

[5] Yamashita J, McCauley LK, Van Poznak C. Updates on osteonecrosis of the jaw. Current

[6] Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. The New England Journal of Medicine. 2009;**360**:53-62 [7] Cheung MS, Glorieux FH, Rauch F. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. Journal of Bone and Mineral Research.

[8] Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in Beagle

[9] Bertoldo F et al. Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle.

[10] Aghaloo TL, Kang B, Sung EC, et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. Journal of Bone and Mineral Research. 2011;**26**:

[11] Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert

[12] Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [Rhpth

[13] Kwon YD, Lee DW, Choi BJ, et al. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporosis International.

Opinion on Drug Metabolism & Toxicology. 2015 Mar;**11**(3):461-470

(1-34)]. Journal of Oral and Maxillofacial Surgery. 2007;**65**:573-580

Surgery. 2011;**39**(4):272-277

2009;**24**:669-674

1871-1882

2012;**23**(11):2721-2725

Oral and Maxillofacial Surgery. 2009;**67**(Suppl 1):2-12

Opinion in Supportive and Palliative Care. 2010;**4**:200-206

dogs. Journal of Bone and Mineral Research. 2010;**25**:98-105

Nature Clinical Practice Oncology. 2007;**4**(12):711-721

Clinical recommendation and subsequent treatment should be assessed by the treating physician based on the patient's status and their needs and preferences, which should alleviate their difficulties and improve the quality of life of the patient suffering from the osteonecrosis of the jaw. Compliance with preventive measures before and during the antiresorptive treatment seems beneficial; however, it is also considerably complicated.

The ARM-induced osteonecrosis of the jaw poses a current problem with a number of yet unanswered questions. In general, it is believed that the cause of the osteonecrosis is multifactorial, dependent not only on administered preparations, but also on the underlying oncological disease, type of chemotherapy, hormonal treatment, associated illnesses, age and addiction case history. It is therefore necessary to correctly set up and indicate the pharmacological and surgical treatment, monitor the bone antiresorptive therapy, with focus on prevention and complications.
